David M. Jackman

12.5k citations

87 papers · 7.6k indexed · 4 hit papers · h-index 38

Pulmonary and Respiratory Medicine top 0.2%
Oncology top 0.2%
Molecular Biology top 5%
Cancer Research top 1%
Pathology and Forensic Medicine top 5%

Co-authors: Bruce E. Johnson Pasi A. Jänne Geoffrey R. Oxnard Beow Y. Yeap Suzanne E. Dahlberg Lecia V. Sequist Neal I. Lindeman Michael S. Rabin
Topics: Lung Cancer Treatments and Mutations (59 papers)Lung Cancer Research Studies (25 papers)Lung Cancer Diagnosis and Treatment (23 papers)
Cited by: Oncology Pulmonary and Respiratory Medicine Cancer Research
Journals: The Lancet Journal of Clinical Oncology Cancer
Partner nations: United States United Kingdom Netherlands

In The Last Decade

David M. Jackman

86 papers receiving 7.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer

2009 644 citations David M. Jackman, Pasi A. Jänne et al. Journal of Clinical Oncology profile →
Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNA

2014 590 citations Geoffrey R. Oxnard, Cloud P. Paweletz et al. Clinical Cancer Research profile →
Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non–Small-Cell Lung Cancer: Results From the CA209-003 Study

2018 539 citations David M. Jackman, Lecia V. Sequist et al. Journal of Clinical Oncology profile →
MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

2016 493 citations Geoffrey R. Oxnard, David M. Jackman et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by David M. Jackman

Since Specialization

Citations

This map shows the geographic impact of David M. Jackman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David M. Jackman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David M. Jackman more than expected).

Fields of papers citing papers by David M. Jackman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David M. Jackman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David M. Jackman. The network helps show where David M. Jackman may publish in the future.

Co-authorship network of co-authors of David M. Jackman

This figure shows the co-authorship network connecting the top 25 collaborators of David M. Jackman. A scholar is included among the top collaborators of David M. Jackman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David M. Jackman. David M. Jackman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Using Oncology Treatment Pathway Data to Evaluate Serious Illness Communication, Care Utilization, and End-of-Life Care for Patients With Cancer 2024 ·JCO Oncology Practice ·Cody E. Cotner,Angela C. Tramontano,(unknown),(unknown),(unknown),(unknown),(unknown),Charlotta Lindvall,James A. Tulsky,Joseph O. Jacobson,David M. Jackman,Alexi A. Wright,(unknown)	3
2	A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial 2016 ·Clinical Cancer Research ·Masahiko Yanagita,Amanda J. Redig,Cloud P. Paweletz,Suzanne E. Dahlberg,Allison O’Connell,Nora Feeney,Myriam Taibi,David Boucher,Geoffrey R. Oxnard,Bruce E. Johnson,Daniel B. Costa,David M. Jackman,Pasi A. Jänne	92
3	Advanced nodal stage predicts venous thromboembolism in patients with locally advanced non-small cell lung cancer 2016 ·Lung Cancer ·Richard Li,Gretchen Hermann,Elizabeth H. Baldini,Aileen B. Chen,David M. Jackman,David Kozono,Paul L. Nguyen,Anju Nohria,Graham Powell,Raymond H. Mak	16
4	Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in KRAS -Mutant Lung Adenocarcinoma 2015 ·Clinical Cancer Research ·Antonio Calles,Lynette M. Sholl,Scott J. Rodig,Ashley K. Pelton,Jason L. Hornick,Mohit Butaney,Christine Lydon,Suzanne E. Dahlberg,Geoffrey R. Oxnard,David M. Jackman,Pasi A. Jänne	86
5	Five-Year Survival in EGFR -Mutant Metastatic Lung Adenocarcinoma Treated with EGFR-TKIs 2015 ·Journal of Thoracic Oncology ·W. Marston Linehan,Stephanie Cardarella,Christine Lydon,Suzanne E. Dahlberg,David M. Jackman,Pasi A. Jänne,Bruce E. Johnson	252
6	Noninvasive Detection of Response and Resistance in EGFR -Mutant Lung Cancer Using Quantitative Next-Generation Genotyping of Cell-Free Plasma DNAbreakdown → 2014 ·Clinical Cancer Research ·Geoffrey R. Oxnard,Cloud P. Paweletz,Yanan Kuang,Stacy L. Mach,Allison O’Connell,Melissa M. Messineo,Jason J. Luke,Mohit Butaney,Paul T. Kirschmeier,David M. Jackman,Pasi A. Jänne	590
7	Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions 2013 ·Journal of Thoracic Oncology ·Geoffrey R. Oxnard,Peter Lo,Mizuki Nishino,Suzanne E. Dahlberg,Neal I. Lindeman,Mohit Butaney,David M. Jackman,Bruce E. Johnson,Pasi A. Jänne	261
8	Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI 2013 ·Journal of Thoracic Oncology ·Mizuki Nishino,Suzanne E. Dahlberg,Stephanie Cardarella,David M. Jackman,Michael S. Rabin,Hiroto Hatabu,Pasi A. Jänne,Bruce E. Johnson	44
9	The Introduction of Systematic Genomic Testing for Patients with Non–Small-Cell Lung Cancer 2012 ·Journal of Thoracic Oncology ·Stephanie Cardarella,Taylor M. Ortiz,Victoria A. Joshi,Mohit Butaney,David M. Jackman,David J. Kwiatkowski,Beow Y. Yeap,Pasi A. Jänne,Neal I. Lindeman,Bruce E. Johnson	77
10	Genomic profiling of non-small cell lung cancer (NSCLC) for personalized targeted therapy using CT-guided transthoracic needle biopsy (TTNB). 2012 ·Journal of Clinical Oncology ·Ritu R. Gill,Stéphanie Héon,Beow Y. Yeap,Mohit Butaney,Neal I. Lindeman,Michael S. Rabin,David M. Jackman,Pasi A. Jänne,Bruce E. Johnson	3
11	Imaging of Lung Cancer in the Era of Molecular Medicine 2011 ·Academic Radiology ·Mizuki Nishino,David M. Jackman,Hiroto Hatabu,Pasi A. Jänne,Bruce E. Johnson,Annick D. Van den Abbeele	29
12	Current Options for Systemic Therapy in Mesothelioma 2009 ·Seminars in Thoracic and Cardiovascular Surgery ·David M. Jackman	12
13	Recurrent malignant peritoneal mesothelioma: radiological manifestations 2009 ·Abdominal Imaging ·Frederico Souza,(unknown),(unknown),Ciarán Johnston,David M. Jackman,Annick Van den Abbeele,Pablo R. Ros	10
14	Autocrine Production of Amphiregulin Predicts Sensitivity to Both Gefitinib and Cetuximab in EGFR Wild-type Cancers 2008 ·Clinical Cancer Research ·Kimio Yonesaka,Kreshnik Zejnullahu,Neal I. Lindeman,(unknown),David M. Jackman,Feng Zhao,Andrew M. Rogers,Bruce E. Johnson,Pasi A. Jänne	96
15	Treatment of peritoneal mesothelioma in pediatric patients 2008 ·Pediatric Blood & Cancer ·Leigh‐Anne Cioffredi,Pasi A. Jänne,David M. Jackman	11
16	P3-096: Phase II study of erlotinib in chemo–naïve women with advanced pulmonary adenocarcinoma. 2007 ·Journal of Thoracic Oncology ·David M. Jackman,Neal I. Lindeman,Joan Lucca,(unknown),Michael S. Rabin,Judith Marcoux,Mark S. Huberman,Bruce E. Johnson,Pasi A. Jänne	1
17	Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib 2006 ·Clinical Cancer Research ·David M. Jackman,Beow Y. Yeap,Lecia V. Sequist,Neal I. Lindeman,Alison J. Holmes,Victoria A. Joshi,Daphne W. Bell,Mark S. Huberman,Balázs Halmos,Michael S. Rabin,Daniel A. Haber,Thomas J. Lynch,Matthew Meyerson,Bruce E. Johnson,Pasi A. Jänne	491
18	Response to low‐dose ketoconazole and subsequent dose escalation to high‐dose ketoconazole in patients with androgen‐independent prostate cancer 2006 ·Cancer ·Mari Nakabayashi,Wanling Xie,Meredith M. Regan,David M. Jackman,Philip W. Kantoff,William Oh	35
19	Adrenal insufficiency during the late stage of polymicrobial sepsis 2001 ·Critical Care Medicine ·Douglas J. Koo,David M. Jackman,Irshad H. Chaudry,Ping Wang	51
20	Is gut the major source of proinflammatory cytokine release during polymicrobial sepsis? 1999 ·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease ·Douglas J. Koo,Mian Zhou,David M. Jackman,William G. Cioffi,Kirby I. Bland,Irshad H. Chaudry,Ping Wang	24

About David M. Jackman

David M. Jackman is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research, having authored 87 papers that have together received 7.6k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (59 papers), Lung Cancer Research Studies (25 papers) and Lung Cancer Diagnosis and Treatment (23 papers). The work is most often cited by research in Oncology (4.9k citations), Pulmonary and Respiratory Medicine (5.6k citations) and Cancer Research (1.7k citations). David M. Jackman has collaborated with scholars based in United States, United Kingdom and Netherlands. Frequent co-authors include Bruce E. Johnson, Pasi A. Jänne, Geoffrey R. Oxnard, Beow Y. Yeap, Suzanne E. Dahlberg, Lecia V. Sequist, Neal I. Lindeman, Michael S. Rabin, Mohit Butaney and Thomas J. Lynch. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact